ABAnna Bohdanowicz-Pawlak

Anna Bohdanowicz-Pawlak

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Bohdanowicz-Pawlak has a total of 47 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Niealkoholowe stłuszczenie wątroby u kobiet z zespołem wielotorbielowatych jajników — aspekty kliniczne i metaboliczne oraz polimorfizm genu lipazy lipoproteinowej

    by Anna Bohdanowicz-Pawlak, Agnieszka Lenarcik-Kabza, Anna Brona, Justyna Kuliczkowska-Płaksej, Łukasz Łaczmański, Urszula Zaleska -Dorobisz, Andrzej Milewicz

    Introduction: The aim was to assess associations among PCOS and NAFLD, the lipoprotein lipase polymorphism gene, and metabolic disorders in PCOS. Material and methods: In 184 women with PCOS and 125 healthy, premenopausal volunteers, sex steroids, lipids, glucose, insulin, aminotransferases, free androgen index (FAI), HOMA-IR and E2/T were calculated. Hepatic steatosis was determined by ultrasound. Whole genomic DNA was isolated from blood leucocytes. Lipoprotein lipase polymorphisms rs268 and rs328 were analysed by polymerase chain reaction (PCR) and minisequencing. Results: 57.6% of PCOS women had NAFLD, while women without PCOS had NAFLD in 49.6%. PCOS-NAFLD women had higher BMI, WHR and waist circumference compared to women with PCOS without NAFLD and women without PCOS. PCOS-NAFLD women had lower SHBG, E2/T ratio, and higher FAI compared to other groups. ALT levels were higher in PCOS women with NAFLD compared to other groups. PCOS women with and without NAFLD had higher fasting glucose and insulin and HOMA compared to women without PCOS. Women with PCOS had higher triglycerides and lower HDL-C compared to women without PCOS. There was no evidence that evaluated polymorphisms influenced hepatic steatosis in women with and without PCOS. Conclusions: PCOS is not an independent factor influencing NAFLD in women. The influences on NAFLD incidence in women are BMI > 25 kg/m², glucose level > 80 mg/dL, E2/T < 80 and ALT > 19 IU/L as independent factors. Hyperandrogenism in PCOS may increase the risk of NAFLD indirectly by obesity, insulin resistance, and directly by the hepatotoxic effect. Polymorphisms rs328 and rs268 of the lipoprotein lipase gene do not affect the occurrence of NAFLD in women with PCOS or without PCOS. (Endokrynol Pol 2014; 65 (6): 416–421) Introduction: The aim was to assess associations among PCOS and NAFLD, the lipoprotein lipase polymorphism gene, and metabolic disorders in PCOS. Material and methods: In 184 women with PCOS and 125 healthy, premenopausal volunteers, sex steroids, lipids, glucose, insulin, aminotransferases, free androgen index (FAI), HOMA-IR and E2/T were calculated. Hepatic steatosis was determined by ultrasound. Whole genomic DNA was isolated from blood leucocytes. Lipoprotein lipase polymorphisms rs268 and rs328 were analysed by polymerase chain reaction (PCR) and minisequencing. Results: 57.6% of PCOS women had NAFLD, while women without PCOS had NAFLD in 49.6%. PCOS-NAFLD women had higher BMI, WHR and waist circumference compared to women with PCOS without NAFLD and women without PCOS. PCOS-NAFLD women had lower SHBG, E2/T ratio, and higher FAI compared to other groups. ALT levels were higher in PCOS women with NAFLD compared to other groups. PCOS women with and without NAFLD had higher fasting glucose and insulin and HOMA compared to women without PCOS. Women with PCOS had higher triglycerides and lower HDL-C compared to women without PCOS. There was no evidence that evaluated polymorphisms influenced hepatic steatosis in women with and without PCOS. Conclusions: PCOS is not an independent factor influencing NAFLD in women. The influences on NAFLD incidence in women are BMI > 25 kg/m², glucose level > 80 mg/dL, E2/T < 80 and ALT > 19 IU/L as independent factors. Hyperandrogenism in PCOS may increase the risk of NAFLD indirectly by obesity, insulin resistance, and directly by the hepatotoxic effect. Polymorphisms rs328 and rs268 of the lipoprotein lipase gene do not affect the occurrence of NAFLD in women with PCOS or without PCOS. (Endokrynol Pol 2014; 65 (6): 416–421)


  • Renal aspects of primary hyperparathyroidism

    by Jadwiga Szymczak, Anna Bohdanowicz-Pawlak, Joanna Jakubowska

    Introduction: Nephrolithiasis and bone disease are the most common complications of primary hyperparathyroidism (PHPT). The aim of this study was to evaluate the relationships between the existence of kidney stones, renal function and bone mineral density (BMD) in PHPT. Description of methods/design: Biomedical evaluation, BMD measurements and renal ultrasonography were performed in a group of 75 consecutive PHPT patients aged 57.6±12.7 years. The control group consisted of 47 generally healthy volunteers. 30 patients with PHPT were subsequently investigated again one year after effective parathyroidectomy (PTX). Results: Osteoporosis occurred in 72% and nephrolithiasis or nephrocalcinosis in 60% of patients with PHPT. There was no significant difference in glomerular filtration rate (GFR), parathormone, calcemia, calciuria, serum vitamin 25(OH)D, bone turnover markers and BMD between patients with and without renal stones. However, in patients with nephrolithiasis serum 1,25(OH)2D concentration was higher (P=0.019), phosphate concentration was lower (P=0.009) and only a slight tendency to a higher GFR and serum osteocalcin was observed. The mean GFR of the whole group (88.3±29.3 ml/min/1.73 m2) was lower (P=0.019) than in controls (104.8±25.1). 84% of the PHPT patients displayed a GFR greater than 60 ml/min/1.73 m2 and thus above the recommended indication level for parathyroidectomy. However, even within this subgroup GFR was lower than in controls. GFR did not change following parthyroidectomy, although the severity of nephrolithiasis has decreased in many patients. Conclusions: Nephrolithiasis does not seem to be the only cause of GFR reduction in PHPT. Since there is no certainty that the reduction in GFR in symptomatic PHPT is reversible after PTX, decisions regarding surgery should not be delayed even in mild cases. There is no clear correlation between BMD and the formation of kidney stones.

  • Does polycystic ovary syndrome influence incidence nonalcoholic fatty liver disease in women?

    by Anna Bohdanowicz-Pawlak, Lukasz Laczmanski, Andrzej Milewicz

    The aim was to assess associations among metabolic abnormalities in polycystic ovary syndrome (PCOS) and NAFLD. Materials and methods: In 184 women with PCOS and 125 healthy premenopausal volunteers sex steroids, lipids, glucose, insulin, aminotranspherases, CRP, free androgen index (FAI), HOMA and E2:testosterone were calculated. Hepatic steatosis was determined by ultrasound. The analysis of multivariate (logistic regression) due to the presence of NAFLD among both groups (141 with NAFLD and 168 without NAFLD) was preformed. For the analysis introduced: BMI, waist circumference, WHR, testosterone, SHBG, FAI, E2:testosterone, AST, ALT, LDL-C, HDL-C, TG, CRP, glucose, insulin, HOMA, and PCOS. Results: 56.7% of PCOS women had NAFLD while women without PCOS had NAFLD in 49.6%. PCOS–NAFLD women had higher BMI, WHR and waist circumference compared to women with PCOS without NAFLD and women without PCOS. PCOS-NAFLD women had lower SHBG, E2/T ratio and higher FAI compared to other groups. ALT levels were higher in PCOS-NAFLD women than in other groups. PCOS women with and without NAFLD had higher fasting glucose, insulin and HOMA-IR than women without PCOS. PCOS women had higher TG and lower HDL-C than women without PCOS. Logistic regression showed that all of the analyzed factors influence NAFLD but BMI>25 kg/m2, E2/T19 IU/l, and glucose>85 mg/dl were independent factors. Conclusions: NAFLD is more common in women with PCOS than in women without PCOS. PCOS affects the development of NAFLD in women, but is not independent factor. Hyperandrogenism in PCOS may increase the risk of NAFLD indirectly by obesity, insulin resistance, and directly by the hepatotoxic effect.

  • Interdisciplinary aspects of primary hyperparathyroidism: symptomatology in a series of 100 cases (single-centre experience)

    by Anna Jodkowska, Krzysztof Tupikowski, Jadwiga Szymczak, Anna Bohdanowicz-Pawlak, Marek Bolanowski, Grazyna Bednarek-Tupikowska

    Introduction: Primary hyperparathyroidism (PHPT) is a common endocrine disorder. Beside renal and skeletal complications, it has a wide variety of nonspecific symptoms from other organs that may mimic other diseases and delay the diagnosis. Nowadays PHPT evolves to less-symptomatic. Aim: The aim is to revise symptomatology profile of PHPT in a single region of Poland; and to help early PHPT diagnosis – encouraging interdisciplinary contact between medical professionals. Methods: We analyzed retrospectively data of 100 patients with PHPT diagnosed in our centre during the past decade: 94 women and six men, aged averagely 57.1 years (S.D. 13.7 years). We evaluated biochemical conditions (hypocalcaemia, hypercalciuria, hypophosphatemia, and PTH level elevation) and clinical manifestations: renal, skeletal, cardiovascular, gastrointestinal, and asymptomatic. Results: Renal symptoms were present in 55%, as isolated symptoms in 14%. In the course of unrecognized disease seven cases of lithotripsy, seven operative lithotomies, two nephrectomies were performed. Osteoporosis/osteopenia was present in 66 and 10% respectively, and in 35% as the only PHPT presentation. In 16% fragility fractures, in 10% brown tumors were present. Fifty-five percent of PHPT patients were hypertensive and 21% ischemic heart disease positive. Gastrointestinal symptoms were present in 52%, in three cases (5.8% of 52), pancreatitis was documented. The incidental diagnosis of PHPT in asymptomatic patients was held in 15%. Mean serum Ca was 2.87 mmol/l (S.D.: 0.36), mean urine Ca was 15.97 mEq/24 h (S.D. 7.89), mean serum iPTH was: 324.11 pg/ml (S.D. 425.21). The duration time from any symptom appearance to the diagnosis varied between immediate diagnosis (19%), 1–10 years (46%), and >10 years (35%). Conclusion: PHPT is still diagnosed too late, usually after a long time of untreated symptomatic disease. There is a need of active PHPT search. Multidisciplinary cooperation between specialists on the diagnostic level brings hope to avoid late complications of unrecognized disease.

  • Open Access

    Effects of radioiodine administration on serum concentrations of matrix metalloproteinases, adiponectin and thrombospondin-1

    by Andrzej Lewinski, Anna Brona, Krzysztof C Lewandowski, Diana Jedrzejuk, Anna Bohdanowicz-Pawlak, Elżbieta Skowronska-Jozwiak, Małgorzata Bienkiewicz, Andrzej Milewicz

    In order to assess safety of radioactive iodine administration in the treatment of thyrotoxicosis, we measured concentrations of matrix metalloproteinase-2 (MMP-2), its main inhibitor – TIMP-2 (tissue inhibitor of MMP-2), matrix metalloproteinase-9 (MMP-9), its main inhibitor – TIMP-1, adiponectin, as well as pro-inflammatory and procancerogenic thrombospondin-1 (TSP-1).


    • 1 January 2013
      • Vol. 34  (2) , 107-10

    Primary hyperparathyroidism presenting as a giant cell tumor of the jaws.

    by Wojciech Pawlak, Anna Bohdanowicz-Pawlak, Marek Bolanowski, Jadwiga Szymczak, Grazyna Bednarek-Tupikowska, Klaudiusz Luczak

    Giant cell tumors of the maxillofacial skeleton are uncommon, they are usually late manifestation of primary hyperparathyroidism. A series of five clinical cases in four women and one man presenting as the giant cell lesions in the maxilla and/or mandible are discussed. Biopsy of the lesions, biochemical and hormonal analyses, densitometry and parathyroid scintigraphy were carried out. Biopsy of the lesions showed giant cell tumor of bone. The medical history and laboratory analyses showed primary hyperparathyroidism. Bone density loss was documented and scintigraphy revealed the presence of parathyroid adenomas in four cases. Surgical treatment of hyperparathyroidism, and in the second step - after 6-12 months - the subsequent excision of residual brown tumors in all cases was performed. One should have in mind that osteolytic bone lesions may be due to metabolic disease of the bone. Accurate diagnosis enabling the proper treatment should be carried out, avoiding unnecessary harm to the patients.


    • 1 January 2013
      • Vol. 64  (3) , 186-91

    Subclinical Cushing's syndrome in adrenal incidentalomas--possible metabolic consequences.

    by Anna Bohdanowicz-Pawlak, Jadwiga Szymczak, Ewa Waszczuk, Marek Bolanowski, Grażyna Bednarek-Tupikowska

    The presence of subclinical Cushing's syndrome (SCS) and some features of the metabolic syndrome were evaluated in adrenal incidentaloma patients. 165 patients were studied. Plasma cortisol, ACTH, DHEA-S, 17-OH-P, aldosterone, renin activity and 24-h urinary methoxycatecholamines were measured. Fasting concentrations of glucose, insulin, triglycerides, T-chol., HDL-chol. and LDL-chol. were determined and the FIRI and QUICKI indices were calculated. Blood pressure, WHR and BMI were determined in all patients. Forty healthy volunteers were the controls. 133 patients had unchanged endocrine function, 32 demonstrated hormonal disturbances without clinical symptoms (in 26 nonclinical hypercortisolism). The WHR and blood pressure in the SCS group were significantly higher than in the patients with nonfunctioning adenoma (NA). T-chol and LDL-chol were significantly higher, but HDL-chol was significantly lower, in the SCS than in the NA patients. Fasting insulin level was significantly higher in the SCS than in the NA patients and controls, while fasting glucose level was comparable. QUICKI was significantly lower in the SCS and NA patients than in the controls, while FIRI was significantly higher in the SCS group. In incidentaloma patients, hormonal function of the adrenal gland should be estimated because some of them present subclinical hyperfunction. These patients frequently display features of metabolic syndrome such as insulin resistance, hypertension, high triglycerides, T-chol and LDL-chol levels. Subtle autonomous cortisol secretion may be the cause of these features.


    • 1 January 2013
      • Vol. 34  (7) , 610-4

    Parathyroid adenoma diagnosed on the basis of a giant cell tumor of parieto-occipital region and multifocal bone injuries.

    by Anna Bohdanowicz-Pawlak, Jadwiga Szymczak, Joanna Jakubowska, Diana Jedrzejuk, Andrzej Pawlak, Tadeusz Lukienczuk, Marek Bolanowski

    Brown tumors are rare skeletal manifestations of hyperparathyroidism (HPT) that may mimic cancer metastases. Histopathologically, they are difficult to differentiate from other giant cell lesions. A case is presented of 41-year-old woman with giant cell tumor in parieto-occipital region with injury of external bone lamina, growing into the skull cavity. The mass was suspected of being neoplastic. Numerous osteolytic lesions in the skull skeleton and multifocal bone injuries were observed, also. Elevation in calcium (5.91 mEq/L) and parathormone (1188 ng/mL) concentrations and hypercalciuria (52 mEq/24 h) suggested the diagnosis of HPT initially manifesting as a brown tumor of the skull. Further exploration confirmed the existence of parathyroid adenoma as a cause of the disease. The key treatment for the condition was surgical excision of the adenoma followed by the normalization of parathyroid function and significant reduction in size of skull tumor and other lesions.


    • 1 January 2012
      • Vol. 63  (4) , 270-6

    Low bone mineral density in adult patients with coeliac disease.

    by Jadwiga Szymczak, Anna Bohdanowicz-Pawlak, Ewa Waszczuk, Joanna Jakubowska

    Calcium and vitamin D malabsorption in coeliac disease (CD) predispose to skeletal demineralisation. The aim of this study was to evaluate the prevalence of bone mineral density (BMD) and calcium deficiencies in adult patients with CD and assess whether a gluten-free diet is sufficiently effective for BMD restoration. BMD and biochemical parameters of bone and mineral metabolism were measured in 35 adult CD patients receiving (19) or not receiving (16) a gluten-free diet (GFD) and in 36 controls. Then the CD patients were treated with a GFD and calcium (1.0 g/day) plus alfacalcidol (0.25-1 μg/day) for one year. Reduced BMD was diagnosed in 57-77% of the patients. Mean calcaemia, calciuria, and 25(OH) vitamin D were lower, but serum PTH and bone-turnover markers (ALP, osteocalcin, ICTP) were significantly higher in the CD patients than in the controls. In the patients on the diet (GFD(+)), BMD was higher than in the GFD(-) patients, but lower than in the controls. The biochemical parameters were normal in the GFD(+) patients except for diminished calciuria. Mean BMD after one year of treatment significantly increased (p < 0.05), mostly in the lumbar spine (mean: 7.3%), but decreased in five patients who did not strictly adhere to the GFD. Deficiencies in calcium, vitamin D, and BMD are very common in adult CD patients. Gluten avoidance increased BMD, although the values remained markedly lower in several patients. Because of chronic calcium deficiency despite GFD, calcium and vitamin D supplementation in most adult CD patients is proposed.


    • 1 January 2011
      • Vol. 62  (5) , 409-15

    Fibrinogen and D-dimers levels in patients with hyperthyroidism before and after radioiodine therapy.

    by Anna Brona, Anna Bohdanowicz-Pawlak, Diana Jędrzejuk, Andrzej Milewicz

    Various abnormalities of haemostasis have been described in patients with hyperthyroidism. The results of different studies point to the underlying thyroid disease, especially severity of hyperthyroidism and autoimmune processes, as important factors contributing to coagulation-fibrinolytic balance. The objective of this study was to investigate the association between hyperthyroidism (concerning severity of thyroid dysfunction and anti-thyroid perioxidase antibodies level) and plasma fibrinogen and D-dimers levels before and after radioiodine therapy. The study included 35 non-smoking, postmenopausal women, aged 51-69, with subclinical or overt hyperthyroidism treated with radioiodine. Analysis comprised serum TSH (thyroid stimulating hormone), fT4 (free thyroxine), fT3 (free triiodothyronine), TPO antibodies (anti-thyroid perioxidase) levels, and plasma D-dimers and fibrinogen levels before and 12-16 weeks and 24-28 weeks after radioiodine therapy. Elevated fibrinogen (3.82 g/L ± 0.75, reference range 2-4.5 g/L) and D-dimers (674.26 ng/mL ± 652.71, reference range 70-490 ng/mL) levels were observed in subjects with hyperthyroidism. They decreased after radioiodine therapy. A negative correlation between plasma fibrinogen and D-dimers levels and anti-thyroid perioxidase antibodies level was found. TSH, fT4 and fT3 correlated with D-dimers level in overt hyperthyroidism. Hyperthyroidism is associated with a tendency toward hypercoagulation and hyperfibrinolysis. The changes observed in plasma fibrinogen and D-dimers levels are reversible. Fibrinogen level decreases within reference range and D-dimers level decreases almost to the upper reference range. They depend on severity and autoimmunity of the underlying thyroid disease and may be modified by restoring euthyroidism.